Recursion Pharmaceuticals Q4 Loss Narrows, Revenue Rises
MT Newswires Live
Yesterday
Recursion Pharmaceuticals (RXRX) reported a Q4 loss Wednesday of $0.21 per diluted share, narrowing from a loss of $0.53 a year earlier.
Analysts polled by FactSet expected a loss of $0.31.
Revenue for the quarter ended Dec. 31 was $35.5 million, up from $4.5 million a year earlier.
Analysts surveyed by FactSet expected $24.5 million.
As of Dec. 31, Recursion said it had $753.9 million in cash and cash equivalents, which it expects to provide it with a cash runway through early 2028.
Shares of the company were up more than 12% in recent Wednesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.